共 46 条
- [41] Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houede, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011 EUROPEAN UROLOGY, 2023, 84 (01) : E22 - E23
- [42] Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7 EUROPEAN UROLOGY, 2019, 75 (03) : E56 - E56
- [43] Reply to Mustafa Aldemir and Abdullah Erdem Canda's Letter to the Editor re: Per-Uno Malmstrom, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247-56 EUROPEAN UROLOGY, 2010, 58 (02) : E24 - E25
- [44] Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation EUROPEAN UROLOGY, 2017, 72 (03) : E64 - E65
- [45] Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol 2020;78:822-830. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer EUROPEAN UROLOGY, 2021, 79 (01) : E12 - E13
- [46] Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients EUROPEAN UROLOGY, 2016, 70 (02) : E42 - E42